Group 1 - Company Medu Technology (02158.HK) announced a share buyback on December 11, 2023, spending HKD 2.682 million to repurchase 535,000 shares [1] - The buyback price ranged from HKD 4.96 to HKD 5.08 per share [1]

智通财经APP讯，医渡科技(02158)公布，2025年12月11日耗资约268.16万港元回购53.5万股股份。 ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | 於下列日期開始時的結存(註1) | 2025年12月9日 | | 1,062,433,231 | 8, ...

Core Viewpoint - In the context of ongoing adjustments in the Hong Kong stock market, Yidu Tech (02158) has demonstrated its intrinsic value and management confidence through a series of solid buyback operations and significantly improved interim performance [1] Buyback Operations - On December 9, Yidu Tech announced a buyback of 345,000 shares at a price of HKD 5.15 per share, amounting to approximately HKD 1.78 million [1] - The company has implemented buybacks for five consecutive trading days, totaling around 1.42 million shares and exceeding HKD 7.3 million in total buyback amount [1] Financial Performance - For the interim results of the fiscal year 2026, Yidu Tech reported total revenue of RMB 358 million, representing a year-on-year growth of 8.7% [1] - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year, with the company nearing breakeven on the accounting level, achieving this milestone about a year ahead of management's original expectations [1] Market and Industry Trends - According to Guosen Securities, the short-term adjustment in the Hong Kong stock market provides space for recovery in 2026 [1] - The US dollar index is expected to weaken in early 2026, benefiting the valuation recovery of emerging markets [1] - The AI sector remains a key focus for 2026, driven by the need for accelerated domestic hardware production and the anticipation of more AI applications [1] AI Medical Sector - Yidu Tech operates in the AI medical sector, which is one of the most barrier-protected and demand-driven core scenarios in the "AI empowering various industries" trend [1] - The company's medical large model technology has entered a new phase of "multiple blooming and large-scale landing," evidenced by three dimensions: 1. Deep application in well-known hospitals, with the AI middle platform implemented in over 30 top-tier hospitals, achieving nearly 1,000 high-frequency calls per day in a single hospital [1] 2. Significant improvement in the accuracy of the TNM staging assessment intelligent agent for key specialties [1] 3. Integration of expert wisdom through the digital twin of doctors, allowing broader service of clinical experience to patients [1]

Core Viewpoint - In the context of ongoing adjustments in the Hong Kong stock market, Yidu Tech (02158) has demonstrated its intrinsic value and management confidence through a series of solid buyback operations and significantly improved interim performance [1] Group 1: Buyback Operations - On December 9, Yidu Tech announced a buyback of 345,000 shares at a price of HKD 5.15 per share, totaling approximately HKD 1.78 million [1] - The company has implemented buybacks for five consecutive trading days, accumulating around 1.42 million shares with a total expenditure exceeding HKD 7.3 million [1] Group 2: Financial Performance - For the interim report of the fiscal year 2026, Yidu Tech reported total revenue of RMB 358 million, representing a year-on-year growth of 8.7% [1] - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year, with the company nearing breakeven on its financial statements, achieving this milestone about a year ahead of management's original expectations [1] Group 3: Market and Industry Trends - According to Guosen Securities, the short-term adjustment in the Hong Kong stock market provides space for recovery in 2026, with the US dollar index expected to weaken in early 2026, benefiting the valuation recovery of emerging markets [1] - The AI sector remains a key focus for 2026, driven by the need for accelerated domestic hardware production and the anticipation of more AI applications, with companies increasingly utilizing AI to enhance labor productivity [1] Group 4: Company Positioning in AI Healthcare - Yidu Tech operates in the AI healthcare sector, which is one of the most barrier-rich and demand-driven core scenarios in the "AI empowering various industries" landscape [1] - The company's medical large model technology has entered a new phase of "multiple blooming and large-scale implementation," evidenced by three dimensions: deep application in over 30 top-tier hospitals, significant accuracy improvements in TNM staging assessment, and the integration of expert clinical experience through digital avatars of doctors [1]

智通财经APP讯，医渡科技(02158)公布，2025年12月9日耗资约177.7万港元回购34.5万股股份。 ...

格隆汇12月9日丨医渡科技(02158.HK)公告，12月9日耗资177.7万港元回购34.5万股，回购价格每股5.13- 5.16港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年12月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 佔 ...

12月8日，医渡科技(02158)发布公告显示，公司当日以每股5.24港元的价格回购22.5万股，回购金额约 118万港元。至此，公司已连续四个交易日实施回购，累计回购约108万股，总金额超550万港元，持续 传递对业务发展的坚定信心。 此前，医渡科技披露2026财年中期业绩并举办发布会，交出稳健增长的成绩单：报告期内总收入达人民 币3.58亿元，同比增长8.7%；盈利质量与运营效率实现关键突破，现有业务经调整EBITDA约5400万 元，较去年同期翻倍，会计报表层面几近盈亏平衡。这一核心财务里程碑的达成，较公司管理层原预期 提前约一年，彰显业务模式的可持续性与增长潜力。 截至12月8日收盘，医渡科技股价报5.24港元，涨0.96%。 业务落地与行业认可再添硕果。近日，医渡科技与山东省潍坊市卫生健康委员会联合申报的"健康画 像"及"潍坊市全民健康数字画像"项目，凭借前瞻性的服务模式与突出的惠民成效，成功斩获两项省级 重磅奖项——2025年山东省"互联网+医疗健康"创新应用案例"惠民服务实践一等奖"、2025年首届"齐鲁 数智医疗健康"创新大赛"服务创新一等奖"，成为AI医疗技术赋能区域健康管理的标杆案例。 ...

业务落地与行业认可再添硕果。近日，医渡科技与山东省潍坊市卫生健康委员会联合申报的"健康画 像"及"潍坊市全民健康数字画像"项目，凭借前瞻性的服务模式与突出的惠民成效，成功斩获两项省级 重磅奖项——2025年山东省"互联网+医疗健康"创新应用案例"惠民服务实践一等奖"、2025年首届"齐鲁 数智医疗健康"创新大赛"服务创新一等奖"，成为AI医疗技术赋能区域健康管理的标杆案例。 截至12月8日收盘，医渡科技股价报5.24港元，涨0.96%。 智通财经APP获悉，12月8日，医渡科技(02158)发布公告显示，公司当日以每股5.24港元的价格回购22.5 万股，回购金额约118万港元。至此，公司已连续四个交易日实施回购，累计回购约108万股，总金额超 550万港元，持续传递对业务发展的坚定信心。 此前，医渡科技披露2026财年中期业绩并举办发布会，交出稳健增长的成绩单：报告期内总收入达人民 币3.58亿元，同比增长8.7%；盈利质量与运营效率实现关键突破，现有业务经调整EBITDA约5400万 元，较去年同期翻倍，会计报表层面几近盈亏平衡。这一核心财务里程碑的达成，较公司管理层原预期 提前约一年，彰显业务模式的可持 ...